Exploiting protease activation for therapy

被引:18
作者
Bleuez, Chloe [1 ,2 ]
Koch, Wolfgang F. [1 ,2 ]
Urbach, Carole [3 ]
Hollfelder, Florian [2 ]
Jermutus, Lutz [1 ]
机构
[1] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Cambridge, England
[2] Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge, England
[3] AstraZeneca, R&D, Biol Engn, Cambridge, England
基金
欧盟地平线“2020”;
关键词
Protease; Proteolytic activation; Zymogen; Cytokine; Antibody engineering; Therapeutic antibodies; Activatable therapeutics; MATRIX-METALLOPROTEINASE INHIBITORS; COMPLEMENT THERAPEUTICS; PEPTIDE INHIBITOR; CANCER-THERAPY; FUSION PROTEIN; IN-VIVO; ANTIBODY; BINDING; SAFETY; PERIODONTITIS;
D O I
10.1016/j.drudis.2022.03.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Proteases have crucial roles in homeostasis and disease; and protease inhibitors and recombinant proteases in enzyme replacement therapy have become key therapeutic applications of protease biology across several indications. This review briefly summarises therapeutic approaches based on protease activation and focuses on how recent insights into the spatial and temporal control of the proteolytic activation of growth factors and interleukins are leading to unique strategies for the discovery of new medicines. In particular, two emerging areas are covered: the first is based on antibody therapies that target the process of proteolytic activation of the pro-form of proteins rather than their mature form; the second covers a potentially new class of biopharmaceuticals using engineered, proteolytically activable and initially inactive pro-forms of antibodies or effector proteins to increase specificity and improve the therapeutic window.
引用
收藏
页码:1743 / 1754
页数:12
相关论文
共 123 条
[1]   Targeting cytokines to inflammation sites [J].
Adams, G ;
Vessillier, S ;
Dreja, H ;
Chernajovsky, Y .
NATURE BIOTECHNOLOGY, 2003, 21 (11) :1314-1320
[2]   Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme [J].
Afonina, Inna S. ;
Muller, Christina ;
Martin, Seamus J. ;
Beyaert, Rudi .
IMMUNITY, 2015, 42 (06) :991-1004
[3]   Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy [J].
Ager, Eleanor I. ;
Kozin, Sergey V. ;
Kirkpatrick, Nathaniel D. ;
Seano, Giorgio ;
Kodack, David P. ;
Askoxylakis, Vasileios ;
Huang, Yuhui ;
Goel, Shom ;
Snuderl, Matija ;
Muzikansky, Alona ;
Finkelstein, Dianne M. ;
Dransfield, Daniel T. ;
Devy, Laetitia ;
Boucher, Yves ;
Fukumura, Dai ;
Jain, Rakesh K. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (04)
[4]   Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9 [J].
Appleby, Todd C. ;
Greenstein, Andrew E. ;
Hung, Magdeleine ;
Liclican, Albert ;
Velasquez, Maile ;
Villasenor, Armando G. ;
Wang, Ruth ;
Wong, Melanie H. ;
Liu, Xiaohong ;
Papalia, Giuseppe A. ;
Schultz, Brian E. ;
Sakowicz, Roman ;
Smith, Victoria ;
Kwon, Hyock Joo .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (16) :6810-6820
[5]   Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents [J].
Assi, Hikmat H. ;
Wong, Chihunt ;
Tipton, Kimberly A. ;
Mei, Li ;
Wong, Ken ;
Razo, Jennifer ;
Chan, Chanty ;
Howng, Bruce ;
Sagert, Jason ;
Krimm, Michael ;
Diep, Linnea ;
Jang, Andrew ;
Nguyen, Margaret T. ;
Lapuyade, Nicole ;
Singson, Victoria ;
Villanueva, Ruth ;
Paidhungat, Madan ;
Liu, Shouchun ;
Rangan, Vangipuram ;
Vasiljeva, Olga ;
West, James W. ;
Richardson, Jennifer H. ;
Irving, Bryan ;
Daniel, Dylan ;
Belvin, Marcia ;
Kavanaugh, W. Michael .
CANCER IMMUNOLOGY RESEARCH, 2021, 9 (12) :1451-1464
[6]   Novel insights into the treatment of complement-mediated hemolytic anemias [J].
Berentsen, Sigbjorn ;
Hill, Anita ;
Hill, Quentin A. ;
Tvedt, Tor Henrik Anderson ;
Michel, Marc .
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
[7]  
Berezhnoy A, 2021, 706 CONDITIONAL C S2, V9, pA735
[8]  
Boni V, 2020, J CLIN ONCOL, V38
[9]   EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies [J].
Boustany, Leila M. ;
Wong, Laurie ;
White, Clayton W. ;
Diep, Linnea ;
Huang, Yuanhui ;
Liu, Shouchun ;
Richardson, Jennifer H. ;
Kavanaugh, W. Michael ;
Irving, Bryan A. .
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[10]   Interleukins in cancer: from biology to therapy [J].
Briukhovetska, Dania ;
Dorr, Janina ;
Endres, Stefan ;
Libby, Peter ;
Dinarello, Charles A. ;
Kobold, Sebastian .
NATURE REVIEWS CANCER, 2021, 21 (08) :481-499